🇺🇸 FDA
Patent

US 8344138

Triazinedione derivatives as GABAB receptor modulators

granted A61PA61P1/00A61P1/04

Quick answer

US patent 8344138 (Triazinedione derivatives as GABAB receptor modulators) held by Addex Pharma, S.A. expires Mon Dec 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Addex Pharma, S.A.
Grant date
Tue Jan 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61P, A61P1/00, A61P1/04, A61P1/14, A61P13/10